Top Life Sciences Stocks To Watch For 2014

Expert healthcare company watcher Andrew Fein of H.C. Wainwright & Co. knows how the sausage is made in the stock analyst factory. And he doesn't pull any punches: In this interview with The Life Sciences Report, Fein dishes out praise for sticking to sellside fundamentals and suggests skimming off bloggers who have yet to earn their analytical chops. He rounds out the menu by naming biotech companies with the potential to rise to the top of the simmering biotech market.

The Life Sciences Report: How has the nature of biotech investing changed since you began analyzing healthcare biotech equities in 2000?

Andrew Fein: Clearly, the web as a source of "investment analytics" is a new paradigm. With so much collectively generated information available on the web, investors are forgetting to analyze individual data points, such as talking directly to physicians and medical experts. Folks who write opinionated investment blogs and emit endless Twitter streams are disproportionately influencing the movement of stocks outside of the traditional analytical Wall Street paradigm. There is always room for new and thoughtful analysis, but it is troubling when the background of the source of what is promoted as important information is unclear. And, unfortunately, hidden biases and agendas often influence the opinion of the non-traditional analyst - such as trying to pump up his or her book.

Top 10 Freight Stocks To Own Right Now: Nissan Motor Co Ltd (NSANF)

NISSAN MOTOR CO., LTD. is an automobile manufacturer. The Company has two business segments. The Automobile segment is engaged in the manufacturing, trading and distribution of various types of automobiles, marine products and accessories, as well as the research, development and sale of lithium-ion secondary batteries. The Sales Financing segment is engaged in the provision of sales financing, as well as property and casualty insurance services, among others. On November 11, 2013, the Company announced that it had established an Indonesia-based subsidiary, which is engaged in the captive finance business to make loans to the customers of Indonesia. Advisors' Opinion:

• [By Peter Valdes-Dapena]

  "Infiniti is proud to have been a pioneer in automotive crash avoidance and mitigation systems. We will study the result of this new test by IIHS as we continue to develop future technologies," said Nissan (NSANF) spokesman Steve Oldham. Nissan makes Infinity vehicles.

Top Life Sciences Stocks To Watch For 2014: Eutelsat Communications SA (ETL)

Eutelsat Communications SA is a France-based holding company that provides fixed satellite services. It provides four types of services, including broadcast services, such as direct-to-home and professional broadcasting; broadband services, comprising broadband Internet access; telecoms and data services to ensure permanent communications links from all points of the globe, establish or restore communications in an emergency and multicast content; as well as mobile and maritime communications, such as fleet management and on- and off-shore broadband maritime communications. It operates a fleet of satellites covering Europe, the Middle East, North and sub-Saharan Africa, as well as parts of Asia and the Americas. In January 2014, it acquired Satelites Mexicanos, S.A. de C.V. and together with SES SA have completed the sale to EchoStar Corp. of Solaris Mobile Ltd. Advisors' Opinion:

• [By Sofia Horta e Costa]

  Eutelsat Communications SA (ETL) declined 6.2 percent to 21.02 euros after predicting sales will grow by more than 2.5 percent for the year 2013 to 2014. The company, which operates 31 satellites, forecast growth of more than 5 percent for the following two years through June 2016. JPMorgan Chase & Co. cut its price target for the stock to 24 euros from 33 euros, saying analysts��will probably reduce their estimates following the company�� revised guidance.

Top Life Sciences Stocks To Watch For 2014: Polydex Pharmaceuticals Ltd (POLXF.PK)

Polydex Pharmaceuticals Limited, incorporated on June 14, 1979, is engaged in the research, development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company also manufactures bulk pharmaceutical intermediates for the global veterinary pharmaceutical industry. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. Dextran, a generic name applied to certain synthetic compounds formed by bacterial growth on sucrose, is a polymer or giant molecule. The products of the Company include Iron Dextran and Dextran Sulphate. The wholly owned subsidiaries of the Company include Dextran Products Limited (Dextran Products) and Chemdex Inc (Chemdex).

Iron Dextran

Iron Dextran is a derivative of Dextran produced by complexing iron with Dextran. Iron Dextran is injected into pigs at birth as a treatment for anemia. The Company sells Iron Dextran to independent distributors and wholesalers in Europe, the Far East and Canada. Chemdex, Inc. has United States FDA approval for the manufacture and sale of Iron Dextran for veterinary use.

Dextran Sulphate

Dextran Sulphate is a specialty chemical derivative of Dextran used in research applications by the pharmaceutical industry and other centers of chemical research. Dextran Sulphate manufactured by the Company is sold primarily to independent distributors and wholesalers in the United States and Europe as analytical chemical applications.

Advisors' Opinion:

• [By The GeoTeam]

  Polydex Pharmaceuticals (POLXF.PK) Limited, through its subsidiaries, engages in the development, manufacture, and marketing of biotechnology-based products for the human pharmaceutical market. It is also involved with manufacture of bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It primarily offers Dextran and Dextran derivative products.

Top Life Sciences Stocks To Watch For 2014: Onconova Therapeutics Inc (ONTX)

Onconova Therapeutics, Inc. (Onconova), incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways, which promote cancer. It has three clinical-stage product candidates and six preclinical programs. Its preclinical pipeline includes six programs, which target kinases, cellular metabolism or division.

Rigosertib

Rigosertib, the Company�� product candidate, is being tested in a range of ongoing Phase-II and Phase-III clinical trials. The Company is conducting a pivotal phase-III trial of rigosertib under a Special Protocol Assessment (SPA), from the United States Food and Drug Administration (FDA), for higher risk myelodysplastic syndromes (MDS). The Company is also evaluating rigosertib in a Phase-III trial for metastatic pancreatic cancer, in two Phase-II trials for transfusion-dependent lower risk MDS, and in a Phase-II trial for head and neck cancers. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe, as well as orphan drug status for pancreatic cancer in the United States. Baxter Healthcare SA (Baxter), a subsidiary of Baxter International Inc., has commercialization rights for rigosertib in Europe and SymBio Pharmaceuticals Limited (SymBio), has commercialization rights in Japan and Korea. Rigosertib is an inhibitor of two cellular signaling pathways: phosphoinositide 3-kinase (PI3K), and polo-like kinase (PLK), both of which are frequently over-active in cancer cells. By inhibiting the PI3K pathway in cancer cells, rigosertib promotes tumor cell apoptosis, or programmed cell death. It is testing both intravenous and oral formulations of rigosertib, referred to as rigosertib IV and rigosertib Oral, in clinical trials.

ON 013105

The Company�� clinical-stage product candidate, ON 013105, is i! n a Phase I trial in patients with relapsed or refractory lymphoma, including an aggressive form of non-Hodgkin's lymphoma identified as mantle cell lymphoma (MCL), and acute lymphoid leukemia (ALL). ON 013105 suppresses the accumulation of cyclin D1 in cancer cells.

Recilisib

The Company�� clinical-stage product candidate, recilisib, is being developed in collaboration with the United States Department of Defense (DoD), for acute radiation syndromes (ARS). The Company has completed four Phase-I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations, referred to as recilisib SC and recilisib Oral.

Preclinical Programs

The Company�� ON 1231320 is a specific inhibitor of Polo-like Kinase 2 (PLK2), and in preclinical studies, it induced mitotic arrest and reduced tumor burden in mice injected subcutaneously with colon tumor and triple-negative breast cancer cells. The Company�� ON 123300 inhibits the activity of two kinases, cyclin-dependent kinase 4 (CDK4), and AMP-activated protein kinase 5 (ARK5). Its ON 108600 is a dual inhibitor of two growth-regulatory kinases. Cyclin-dependent kinase 9 is over expressed in several cancers, including leukemias and lymphomas. Casein kinase 2 is overexpressed in a range of tumor types. ON 044580 inhibits mutant forms of the two target kinases, including Janus Kinase 2 (JAK2) and imatinib-resistant Bcr-Abl Kinase (Bcr-Abl). Its ON 24 compounds cause tubulin to depolymerize, inducing mitotic arrest in cultured tumor cell lines. Its ON 146040 inhibits the growth of a range of blood cancer cell lines, including Burkitt's lymphoma, MCL, multiple myeloma and chronic myeloid leukemia.

The Company competes with Eisai Inc., Celgene Corporation, Genentech, Inc., Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Telik, Inc., Spectrum Pharmaceuticals, Inc., Astex, Array BioPharma Inc., Astellas Pharma, Inc., Threshold! Pharmace! uticals, Inc., Pharmacyclics Inc., Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.

Advisors' Opinion:

• [By gurujx]

  Onconova Therapeutics Inc (ONTX) Reached the 3-year Low of $4.18

  The prices of Onconova Therapeutics Inc (ONTX) shares have declined to close to the 3-year low of $4.18, which is 86.8% off the 3-year high of $31.13.

• [By Roberto Pedone]

   

  Onconova Therapeutics (ONTX), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. This stock closed up 2.5% to $5.15 in Thursday's trading session.

   

  Thursday's Range: $4.97-$5.19
  
  52-Week Range: $4.10-$31.13
  
  Thursday's Volume: 132,000
  
  Three-Month Average Volume: 216,102

   

  From a technical perspective, ONTX trended modestly higher here with lighter-than-average volume. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $4.10 to its recent high of $5.52. During that uptrend, shares of ONTX have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ONTX within range of triggering a near-term breakout trade. That trade will hit if ONTX manages to take out Thursday's intraday high of $5.19 to some more key overhead resistance at $5.52 with high volume.

   

  Traders should now look for long-biased trades in ONTX as long as it's trending above some near-term support levels at $4.80 or at $4.50 and then once it sustains a move or close above those breakout levels with volume that hits near or above 216,102 shares. If that breakout gets underway soon, then ONTX will set up to re-test or possibly take out its next major overhead resistance levels at $5.83 to $6.27. Any high-volume move above those levels will then give ONTX a chance to tag $7.

   

Top Life Sciences Stocks To Watch For 2014: Ingredion Inc (INGR)

Ingredion Incorporated (Ingredion), formerly Corn Products International, Inc., incorporated on March 27, 1997, is a global manufacturer and supplier of starch and sweetener ingredients to a range of industries, including packaged food, beverage, brewing and industrial customers. The Company's product line includes starches and sweeteners, animal feed products and edible corn oil.

The Company's starch-based products include both food-grade and industrial starches. The Company's sweetener products include glucose syrups, high maltose syrups, high fructose corn syrup (HFCS), caramel color, dextrose, polyols, maltodextrins and glucose and syrup solids. The Company's products are derived primarily from the processing of corn and other starch-based materials, such as tapioca, potato and rice.

Sweetener Products

The Company's sweetener products represented approximately 44% of the Company's net sales for the year ended December 31, 2012. Glucose syrups are fundamental ingredients used in food products, such as baked goods, snack foods, beverages, canned fruits, condiments, candy and other sweets, dairy products, ice cream, jams and jellies, prepared mixes and table syrups. Glucose syrups offer functionality in addition to sweetness to processed foods. High Maltose Syrup is special type of glucose syrup, which is primarily used as a fermentable sugar in brewing beers. High maltose syrups are also used in the production of confections, canning and some other food processing applications. The Company's high maltose syrups actually speeds the fermentation process, allowing brewers to increase capacity without adding capital.

High fructose corn syrup is used in a variety of consumer products, including soft drinks, fruit-flavored beverages, baked goods, dairy products, confections and other food and beverage products. In addition to sweetness and ease of use, high fructose corn syrup provides body,humectancy and aids in browning, freezing point and crystalliza! tion control.

Dextrose has a range of applications in the food and confection industries, in solutions for intravenous and other pharmaceutical applications, and numerous industrial applications like wallboard, biodegradable surface agents and moisture control agents. Dextrose functionality in foods, beverages and confectionary includes sweetness control; body and viscosity; acts as a bulking, drying and anti-caking agent; serves as a carrier; provides freezing point and crystallization control; and aids in fermentation. Dextrose is also a fermentation agent in the production of light beer. In pharmaceutical applications dextrose is used in IV solutions as well as an excipient suitable for direct compression in tableting.

Polyols products are sugar-free, reduced calorie sweeteners primarily derived from starch or sugar for the food, beverage, confectionery, industrial, personal and oral care, and nutritional supplement markets. In addition to sweetness, polyols inhibit crystallization; provide binding, humectancy and plasticity; add texture; extend shelf life; prevent moisture migration, and are an excipient suitable for tableting.

Maltodextrins and Glucose Syrup Solids products have a multitude of food applications, including formulations where liquid syrups cannot be used. Maltodextrins are resistant to browning, provide solubility, have a low hydroscopicity (do not retain moisture), and are ideal for their carrier/bulking properties. Glucose syrup solids have a bland flavor, remain clear in solution are easy to handle and provide bulking properties.

Starch Products

The Company's starch products represented approximately 37 % of the Company's net sales for 2012. Starches are an important component in a range of processed foods, where they are used for adhesions, clouding, dusting, expansion, fat replacement, freshness, gelling, glazing, mouth feel, stabilization and texture. Starches are also used in paper production to create a smooth s! urface fo! r printed communications and to improve strength in recycled papers. Specialty starches are used for enhanced drainage, fiber retention, oil and grease resistance, improved printability and biochemical oxygen demand control. Industrial starches are used in the production of construction materials, textiles, adhesives, pharmaceuticals and cosmetics, as well as in mining, water filtration and oil and gas drilling. Specialty starches are used for biomaterial applications including biodegradable plastics, fabric softeners and detergents, hair and skin care applications, dusting powders for surgical gloves and in the production of glass fiber and insulation.

Co-Products and others

Co-products and others accounted for 19% of the Company's net sales for 2012. Refined corn oil (from germ) is sold to packers of cooking oil and to producers of margarine, salad dressings, shortening, mayonnaise and other foods. Corn gluten feed is sold as animal feed. Corn gluten meal is sold as high protein feed for chickens, pet food and aquaculture.

The Company competes with ADM Corn Processing Division (ADM), Cargill, Inc. and Tate & Lyle Ingredients Americas, Inc.

Advisors' Opinion:

• [By Dividends4Life]

  Memberships and Peers: ADM is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: Bunge Limited (BG) with a 1.6% yield, Ingredion Incorporated (INGR) with a 2.4% yield and Griffin Land & Nurseries Inc. (GRIF) with a 0.7% yield.

Top Life Sciences Stocks To Watch For 2014: TriQuint Semiconductor Inc.(TQNT)

TriQuint Semiconductor, Inc. provides radio frequency (RF) solutions and technology for communications, defense, and aerospace companies worldwide. The company designs, develops, and manufactures RF solutions with gallium arsenide (GaAs), gallium nitride, bipolar high electron mobility transistor, surface acoustic wave (SAW), temperature compensated surface acoustic wave, bulk acoustic wave (BAW), copper flip, and wafer level packaging technologies. The company offers an array of filtering, switching, and amplification products for RF, microwave, and millimeter-wave applications. It sells electronic components for mobile phones, including transmit modules, RF filters, power amplifiers and power amplifier modules, duplexers, switches, other RF devices, and integrated products to mobile device manufacturers. The company also offers signal amplification and filtering products, including a portfolio of GaAs microwave monolithic integrated circuits and transistors, and SAW and BAW filter components that support the transfer of voice, data, and video across wireless or wired infrastructure. Its network products comprise millimeter wave power amplifiers, frequency converters, and voltage controlled oscillators. In addition, the company provides defense and aerospace devices, including packaged products, die-level integrated circuits (ICs), microwave monolithic ICs, and multi-chip modules to military contractors serving the U.S. government for use in various communications and phased array radar programs, such as ship-based, airborne, and battlefield systems, as well as sat-com, electronic warfare, and guidance applications. Further, TriQuint Semiconductor, Inc. offers foundry services. The company sells its products through independent manufacturers? representatives, independent distributors, and direct sales staff. TriQuint Semiconductor, Inc. was founded in 1981 and is headquartered in Hillsboro, Oregon.

Advisors' Opinion:

• [By Eric Volkman]

  TriQuint Semiconductor (NASDAQ: TQNT  ) is aiming to boost the value of its shares with a fresh repurchase scheme. The firm announced it has authorized the buyback of up to $75 million worth of its common stock. This will be bought "from time to time in the open market at prevailing market prices or through privately negotiated transactions at the discretion of Company management."

• [By Selena Maranjian]

  Among holdings in which Graham Capital Management increased its stake was TriQuint Semiconductor (NASDAQ: TQNT  ) . The stock recently received an upgrade to "buy" from analysts at Charter Equity, but my colleague Rich Smith thinks the stock is still overvalued. Anyone thinking the stock is on the rich side won't be happy about the company's stock-buyback plans. Its last earnings report was disappointing, but management sees better days ahead due to the introduction of many new products, along with a growing market.

Hot Industrial Conglomerate Stocks To Watch For 2015

Hot Industrial Conglomerate Stocks To Watch For 2015: ThyssenKrupp AG (TKA)

ThyssenKrupp AG is a Germany-based technology holding company operating in seven business areas. The Steel Europe division produces carbon steel flat products. The Steel Americas division is engaged in production, processing and marketing of high-grade carbon steels. The Materials Services division is engaged in global distribution of materials and the provision of complex technical services for the production and manufacturing sectors. The Elevator Technology division is engaged in the area of passenger transportation systems. The Plant Technology division focuses on specialty and large-scale plant construction. The Components Technology division is engaged in manufacturing components for the automotive, construction and engineering sectors as well as for wind turbines. The Marine Systems division focuses on naval and civil shipbuilding. Apart from its business areas, it provides business services, which are diversified into Business Services and Information Technology (IT) Services. Advisors' Opinion:

• [By Corinne Gretler]

  Telekom Austria (TKA) slid 1.6 percent to 5.63 euros. Second-quarter earnings before interest, taxes, depreciation and amortization fell to 330.3 million euros ($439 million) from 364.8 million euros a year earlier. That compared with the average 332.7 million-euro analyst estimate.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-industrial-conglomerate-stocks-to-watch-for-2015-2.html

Top 10 Retail Stocks To Buy Right Now

Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.

What is Acceleron Pharma?

Small cap Acceleron Pharma�� scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-尾) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone and blood vessels.�Based on this expertise, Acceleron Pharma has built a pipeline of protein therapeutics targeted to key mechanisms underlying blood diseases and cancer:

Top 10 Managed Healthcare Companies To Own In Right Now: Gale Pacific Ltd (GAP)

Gale Pacific Limited is an Australia-based company engaged in marketing, sales, manufacture and distribution of screening, shading and home improvement products to global markets.The Company operates in one business segment, being the branded shading, screening and home improvement products. The Company products are sold to consumer and industrial markets including the retail and home furnishing, architectural, construction, and agribusiness markets. The Company manufactures sources and markets advanced durable knitted and woven polymer fabrics and structures made from these fabrics. The Company's retail products are marketed under the Coolaroo brand. The Company's retail product lines include items such as shade fabrics, exterior window furnishings, gazebos, shade sails and a range of pet products. The Company sells its products in Australia, the Unites States, Europe, the Middle East, New Zealand and a number of other export markets. Advisors' Opinion:

• [By Dimitra DeFotis]

  Some trends and percentages:

  Department store Thanksgiving online sales grew by 60% vs 2012, with mobile sales growing by 44% year over year. Perhaps a boost for clothing purveyors like Gap (GAP), whose shares are up 1% in morning trading : total online sales of apparel on Thanksgiving grew by about 41% vs. 2012, with mobile sales growing by close to 62.4% year over year. Shares of�Macy’s�(M) are flat this morning, while shares of women’s clothing seller Chico�� Fas�(CHS) are down 0.4%. Mobile represented nearly 26

Top 10 Retail Stocks To Buy Right Now: Starbucks Corporation(SBUX)

Starbucks Corporation purchases and roasts whole bean coffees. It operates approximately 16,858 stores, including 8,833 company-operated stores and 8,025 licensed stores. The company offers approximately 30 blends and single-origin premium arabica coffees. It also provides handcrafted beverages, such as fresh-brewed coffee, hot and iced espresso beverages, coffee and non-coffee blended beverages, Vivanno smoothies, and Tazo teas; and merchandise products, including home espresso machines, coffee brewers and grinders, coffee mugs and accessories, packaged goods, music, books, and gift items. In addition, it offers fresh food items, which comprise baked pastries, sandwiches, salads, oatmeal, yogurt parfaits, and fruit cups. Further, it also provides VIA ready brew coffee, bottled frappuccino beverages, discoveries chilled cup coffee, doubleshot espresso drinks, iced coffee, whole bean coffee, and ice creams. The company?s brand portfolio includes Tazo tea, Ethos water, Seatt le?s Best Coffee, and Torrefazione Italia Coffee. Starbucks Corporation sells its products in approximately 50 countries worldwide. Starbucks Corporation was founded in 1971 and is based in Seattle, Washington.

Advisors' Opinion:

• [By WWW.DAILYFINANCE.COM]

  CBS/Getty ImagesAre Thurston Howell III and his wife Lovey really the types you should imitate? Would you like to be happy? Of course -- but how? How much income do you need to feel financially secure enough to feel happy? How should you spend the money you make to "buy happiness" -- if that's even possible? In 2012, a website opened up with a mission to quantify happiness and utilize vetted academic data from positive psychology to help lead people to a happy place. Its name: Happify.com. And as luck would have it, Happify.com has just released a short, colorful report on some of its findings. Recognize When Enough's Enough Citing data from a 2010 Princeton University study, Happify notes that an annual income of $75,000 is the sweet spot for personal happiness. After that, "salaries above $75,000 have no impact on our day-to-day feelings of happiness." That seems to defy logic. (If enough is enough, then shouldn't more than enough be better?) But research appears to confirm that after you reach a point of comfortable well-off-ness -- $75,000 being a good benchmark, 50 percent above the median annual household income in America -- you hit a point of diminishing returns. In terms of absolute wealth, once you can comfortably cover life's necessities -- and then some -- a little more cash doesn't matter. It's a different story for those who are focused on relative wealth and status (how much you have vs. your neighbor). In that case, there's always going to be someone you know or read about who's earning more. The research's conclusion: Catching up to Thurston Howell III is an impossible task, and you're more likely to be happy if you don't even try, and just content yourself with being significantly above average for income. Wake Up From the American Dream Another finding cited by Happify challenges the idea that the American dream of homeownership is one key to happiness. According to Happify (and others), "homeowners are ... no happier than renters. O

• [By Michael Vodicka]

  After a highly publicized IPO in April 2000 during the aftermath of the tech bubble, Krispy Kreme Doughnuts (NYSE: KKD) proceeded to surge, climbing from $10 to an all-time high of $49 in the next three years. That fueled massive buzz that the company was well on its way to becoming the next Starbucks (Nasdaq: SBUX) or Dunkin' Brands (Nasdaq: DNKN).

• [By WWW.DAILYFINANCE.COM]

  APBob Marley's name is becoming a brand for marijuana. For decades, Bob Marley has been synonymous reggae music, the Rastafari religion -- and marijuana. The musician reportedly smoked a pound a week as part of his religious practice, according to High Times, and advocated its legalization in the 1970s. Now his name and image will be even more intertwined with the substance, as Marley's family has licensed his name and image to the first international commercial marijuana brand, according to NBC News. The family is working with private equity firm Privateer Holdings and announcing Marley Natural, "a premium cannabis brand rooted in the life and legacy" of the influential musician. The line will include "heirloom Jamaican cannabis" buds, oils and concentrates, of course, along with other products, such as marijuana-infused creams and e-cigarette-like vaporizers. A marketing agency that has worked for New Balance and Starbucks (SBUX) has been retained to help create a modern consumer branding. Spirituality, Well-Being, Reflection, Nature and Liberation When asked by High Times in 1976 if pot would be legalized, Marley answered, "I don' know if dis government will, but I know Christ's government will." Times have changed, high or not, and acceptance of marijuana has advanced, with medical use allowed in dozens of states and a number having passed complete recreational legalization. Now Marley's family is putting his image at the commercial front of the movement. "It just seems natural that Daddy should be part of this conversation," said the singer's oldest daughter, 47-year-old Cedella Marley, according to the Guardian. "He viewed the herb as something spiritual that could awaken our well-being, deepen our reflection, connect us to nature and liberate our creativity." Zion vs. Babylon However, there seems to be a potential existential conflict. As a Rastafari, Marley believed in a division between what is called Zion, a perfect world created by the right

• [By Andrew Marder]

  Yogurt for breakfast is good. Coffee for breakfast is good. Yogurt-coffee might be crossing a hidden line, though. Thankfully, that's apparently not what�Starbucks (NASDAQ: SBUX  ) and Danone� (NASDAQOTH: DANOY  ) had in mind when they recently announced a plan to release yogurt together starting in 2014. The companies both get a benefit from the agreement, with Danone using Starbucks to get more exposure in the American market, while Starbucks gets another arrow in its food-quiver.

Top 10 Retail Stocks To Buy Right Now: Tranzbyte Corp (ERBB)

The Tranzbyte Corporation, incorporated on November 12, 1998, is a driving force behind Altitude Organic Corporation, One Bode, The YO! Debit Card, and ProximaRF. Altitude Organic Corporation is a medical marijuana dispensary brand. It has developed retailing, branding, and commercial cultivating strategies in conjunction with its licensed medical marijuana retail dispensaries operating under the Altitude Organic Medicine brand name.

Tranzbyte houses the technology division, which is engaged in the sale of its optical media enhancement products to customers in the United States and Asia. Products in the Tranzbyte division include FLASHAlbum and FlixStix technologies that enable distributors of optical media (compact discs, digital video discs, etc.) to consolidate the features of each medium onto a single content-protected universal serial bus (USB) flash drive. One Bode has created an assortment of products focusing on plant-based nutrients and enzymes. Applied radio frequency identification (RFID) and its operating subsidiaries (www.proximarf.com), have a portfolio of RFID reader, sensor tag and data logging products.

Advisors' Opinion:

• [By John Udovich]

  The SEC has halted trading of small cap marijuana stock Growlife Inc (OTCMKTS: PHOT) after a relatively brief trading halt for�Advanced Cannabis Solutions, Inc (OTCMKTS: CANN), but Tranzbyte Corp (OTCMKTS: ERBB), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA) are still very much alive. However and as I have noted (repeatedly)�in the past (see here), Medical Marijuana Inc has a�former CEO who has been indicted for a multi-state mortgage fraud scam/ponzi scheme while Medbox Inc (OTCMKTS: MDBX) is another marijuana stock with some ��ssues��that were summed up nicely in a Southern Investigative Reporting Foundation article cleverly entitled: Tinkerer, Lawyer, Hustler, Lies: One Man�� Path to a Dope Fortune. Obviously, investing in marijuana stocks is not for conservative. Nevertheless, there is�still plenty of good or bad news for investors in the marijuana sector to inhale, including the following:

• [By John Udovich]

  Its been a rather eventful week for news from the marijuana sector and small cap marijuana stocks like GW Pharmaceuticals PLC (NASDAQ: GWPH), Tranzbyte Corp (OTCMKTS: ERBB) and Growlife Inc (OTCMKTS: PHOT) as one of these stocks gets endorsed by Morgan Stanley while another appears on CNBC���more signs of legitimacy for an investment�sector that�� full of pumps, dumps and other unsavory types of activities. Just consider the following small cap marijuana stock or pot industry news:

• [By Peter Graham]

  Small cap holding companies Sibling Group Holdings Inc (OTCMKTS: SIBE), Tranzbyte Corp (OTCMKTS: ERBB) and Readen Holding Corp (OTCMKTS: RHCO) are in the business of holding or acquiring other companies. They have also been getting some attention lately in various investment newsletters and not necessarily because of acquisitions or other news but rather because of a few recent paid promotions. With that in mind, here is a quick look and a reality check about all three:

• [By Bryan Murphy]

  Though they've been lumped into the same category as Medical Marijuana Inc. (OTCMKTS:MJNA) and Tranzbyte Corp. (OTCMKTS:ERBB), names like Nuvilex Inc. (OTCMKTS:NVLX) and Growlife Inc. (OTCBB:PHOT) aren't actually marijuana stocks. Granted, PHOT and ERBB shareholders will benefit from the advent of legalized marijuana (and hemp) as much as shareholders of ERBB - a grower and dispenser - and MJNA shareholders will. But, in some way they're safer and more stable because they're not directly in the line of fire of potential regulation... or better-enforced regulation at the federal level. Indeed, there are several stocks that are circumventing the risk inherent with marijuana stocks, because they're not marijuana stocks at all. They are, in no particular order....

Top 10 Retail Stocks To Buy Right Now: AutoCanada Inc (ACQ)

AutoCanada Inc. (AutoCanada) is a multi-location automobile dealership groups. As of December 31, 2011, the Company operated 24 franchised dealerships in British Columbia, Alberta, Manitoba, Ontario, New Brunswick and Nova Scotia. During the year ended December 31, 2011, its dealerships sold approximately 28,000 vehicles and processed approximately 300,000 service and collision repair orders in its 333 service bays. As of December 31, 2011, it was authorized to sell through its dealerships the vehicle brands, which include Chrysler, Dodge, Jeep, Ram, Fiat, Hyundai, Nissan, Infiniti, Volkswagen, Mitsubishi and Subaru. In addition, it sells a range of used vehicles. In November 2011, the Company acquired assets of two dealerships. In January 2013, the Company purchased the assets of a Volkswagen dealership known as People's Automotive Ltd. Advisors' Opinion:

• [By Greg Quinn]

  AutoCanada Inc. (ACQ), the country�� largest publicly traded chain of car dealerships, is using sales of trucks to Alberta oil workers to fund higher dividends and buy out competitors.

Top 10 Retail Stocks To Buy Right Now: Coach Inc (COH)

Coach, Inc. (Coach), incorporated in June 2000, is a marketer of fine accessories and gifts for women and men. Coach�� product offerings include women�� and men�� bag, accessories, business cases, footwear, wearables, jewelry, sunwear, travel bags, watches and fragrance. The Company operates in two segments: Direct-to-Consumer and Indirect. Accessories include women�� and men�� small leather goods, novelty accessories and women�� and men�� belts. Women�� small leather goods, which coordinate with its handbags, include money pieces, wristlets, and cosmetic cases. Men�� small leather goods consist primarily of wallets and card cases. Novelty accessories include time management and electronic accessories. Key rings and charms are also included in this category. Men�� handbag collections include business cases, computer bags, messenger-style bags and totes. Footwear is distributed through select Coach retail stores, coach.com and about 1,000 United States department stores. Wearables category is comprised of jackets, sweaters, gloves, hats and scarves, including both cold weather and fashion.

The Company�� Jewelry category is comprised of bangle bracelets, necklaces, rings and earrings offered in both sterling silver and non-precious metals. Marchon Eyewear, Inc. (Marchon) is the Coach�� eyewear licensee. Coach sunglasses are sold in Coach retail stores and coach.com, department stores, select sunglass retailers and optical retailers in major markets. The travel collections are comprised of luggage and related accessories, such as travel kits and valet trays. Movado Group, Inc. (Movado) is the Company�� watch licensee, which develops a collection of watches.

Estee Lauder Companies Inc. (Estee Lauder), through its subsidiary, Aramis Inc., is Coach�� fragrance licensee. Fragrance is distributed through Coach retail stores, coach.com and about 4,000 United States department stores and 500 international locations. Coach offers four women�� fragrance col! lections and one men�� fragrance. The women�� fragrance collections include eau de perfume spray, eau de toilette spray, purse spray, body lotion and body splashes.

Direct-to-Consumer Segment

The Direct-to-Consumer segment consists of channels that provide the Company with immediate, controlled access to consumers: Coach-operated stores in North America; Japan; Hong Kong, Macau, and mainland China, Taiwan, Singapore and the Internet. This segment represented approximately 89% of Coach�� total net sales during the fiscal year ended June 30, 2012 (fiscal 2012), with North American stores and the Internet, Coach Japan and Coach China contributing approximately 63%, 18% and 6% of total net sales, respectively. Coach stores are located in regional shopping centers and metropolitan areas throughout the United States and Canada. The retail stores carry an assortment of products. Its stores are located in locations, such as New York, Chicago, San Francisco and Toronto.

Coach�� factory stores serve as a means to sell manufactured-for-factory-store product, including factory exclusives, as well as discontinued and irregular inventory outside the retail channel. These stores operate under the Coach Factory name. Coach�� factory store design, visual presentations and customer service levels support. Coach views its Website as a key communications vehicle for the brand to promote traffic in Coach retail stores and department store locations. Its online store provides a showcase environment where consumers can browse through a selected offering of the latest styles and colors.

Coach Japan operates department store shop-in-shop locations and freestanding flagship, retail and factory stores, as well as an e-commerce Website. Flagship stores offer an assortment of Coach products that are located in select shopping districts throughout Japan. Coach China operates department store shop-in-shop locations, as well as freestanding flagship, retail and factory sto! res. Flag! ship stores, which offer an assortment of Coach products, are located in select shopping districts throughout Hong Kong and mainland China. Coach Singapore and Taiwan operate department store shop-in-shop locations as well as freestanding flagship, retail and factory stores. Flagship stores, which offer a range of assortment of Coach products, are located in select shopping districts in Singapore and Taiwan.

The Reed Krakoff brand represents New American luxury primarily for handbags, accessories and ready-to-wear. Reed Krakoff operates department store shop-in-shop locations, freestanding flagship stores, as well as an e-commerce Website at reedkrakoff.com. Flagship stores, which offer an assortment of Reed Krakoff products, are located in select shopping districts in the United States and Japan.

Indirect Segment

The Indirect segment represented approximately 11% of total net sales in fiscal 2012, with United States Wholesale and Coach International representing approximately 6% and 4% of total net sales, respectively. The Indirect segment also includes royalties earned on licensed product. U.S. Wholesale channel offers access to Coach products to consumers who prefer shopping at department stores. Coach products are also available on macys.com, dillards.com, bloomingdales.com, lordandtaylor.com, belk.com, vonmaur.com and nordstrom.com. Coach�� products are sold in approximately 990 wholesale locations in the United States and Canada. Its U.S. wholesale customers are Macy�� (including Bloomingdale��), Dillard��, Nordstrom, Lord & Taylor, Carson�� and Saks Fifth Avenue.

Coach International channel represents sales to international wholesale distributors and authorized retailers. Coach has developed relationships with a select group of distributors who sell Coach products through department stores and freestanding retail locations in over 20 countries. Coach�� network of international distributors serves various markets: South Korea, US & T! erritorie! s, Taiwan, Malaysia, Hong Kong, Mexico, Saudi Arabia, Thailand, Japan, Australia, Singapore, UAE, France, China, Macau, Indonesia, Kuwait, Bahamas, Aruba, Vietnam, New Zealand, Bahrain, India and Brazil.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, luxury handbag maker Coach (NYSE: COH  ) has earned a respected four-star ranking.

• [By WWW.DAILYFINANCE.COM]

  Hong Wu/Michael Kors/Getty Images Here's something that you don't see every day. On Monday, Michael Kors (KORS) posted strong quarterly results with sales and earnings soaring 43 percent and 50 percent, respectively. The stock plunged 6 percent on the news. A day later, rival handbag maker Coach (COH) saw its sales and adjusted earnings decline 7 percent and 35 percent, respectively. The stock opened higher. Wall Street doesn't usually punish growth and reward failure, but it's all relative here. Kors may have blasted through Wall Street's top- and bottom-line targets, but analysts were disappointed in the guidance for the current quarter that Kors provided, suggesting margin contraction and that earnings will fall short of expectations. Coach's quarter was a stinker on the surface, but the market was braced for even more pain. Wall Street pros were forecasting adjusted earnings per share to plunge 40 percent on a double-digit percentage drop in sales. It also didn't hurt that Coach had an upbeat demeanor as it talked up its overseas growth, success with its expanding products for men, and the buzz generated by its new creative director that was brought on board late last year to reinvigorate the brand. It's Never Entirely In the Bag The market this week is suggesting that Coach is bouncing back and that Kors is reeling, but the numbers tell an entirely different story.

  The market's concerned that Kors is following Coach's footsteps down a spiral staircase leading to a clearance rack.

• [By Dividend]

  Coach (COH) has a market capitalization of $14.96 billion. The company employs 18,000 people, generates revenue of $5.075 billion and has a net income of $1.034 billion. Coach�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $1.524 billion. The EBITDA margin is 30.04 percent (the operating margin is 30.04 percent and the net profit margin 20.38 percent).

Top 10 Retail Stocks To Buy Right Now: Office Depot Inc.(ODP)

Office Depot, Inc., together with its subsidiaries, supplies office products and services. Its North American Retail division sells an assortment of merchandise, such as general office supplies, computer supplies, business machines and related supplies, and office furniture under various labels, including Office Depot, Viking Office Products, Foray, Ativa, Break Escapes, Niceday, and Worklife through its chain of office supply stores. It also provides printing, reproduction, mailing, shipping, and other services, as well as personal computer support and network installation service. As of December 25, 2010, this division operated 1,147 office supply stores in the United States and Canada. The company?s North American Business Solutions division sells nationally branded and private brand office supplies, technology products, furniture, and services to small- to medium-sized customers through a dedicated sales force, catalogs, and Internet. Its International division sells o ffice products and services through direct mail catalogs, contract sales forces, Internet sites, and retail stores using a mix of company-owned operations, joint ventures, licensing and franchise agreements, alliances, and other arrangements. As of December 25, 2010, it sold its office products to customers in 53 countries in North America, Europe, Asia, and Latin America. This division operated, through wholly-owned or majority-owned entities, 97 retail stores in France, Hungary, South Korea, and Sweden; and participates under licensing and merchandise arrangements in South Korea, Thailand, India, Israel, Japan, and the Middle East. The company was founded in 1986 and is headquartered in Boca Raton, Florida.

Advisors' Opinion:

• [By Rich Bieglmeier]

  Office Depot Inc. (NYSE:ODP) will announce first quarter 2014 results for the fiscal period ending March 29, 2014 on Tuesday, May 6, 2014. A conference call to discuss the results will be held that day at 9:00 a.m. Eastern Time.

• [By Charley Blaine]

  Shares of Office Depot (NYSE: ODP) got a boost, shooting up 3.5 percent to $5.79 after the Federal Trade Commission closed a probe of the company's proposed merger with OfficeMax (NYSE: OMX).

• [By Jake L'Ecuyer]

  Shares of Office Depot (NYSE: ODP) got a boost, shooting up 3.94 percent to $5.81 after the US Federal Trade Commission closed probe of proposed Office Depot/OfficeMax merger.

Top 10 Retail Stocks To Buy Right Now: Burberry Group PLC (BRBY)

Burberry Group plc (Burberry) is a holding company. The Company designs and sources luxury apparel and accessories, selling through a diversified network of retail (including digital), wholesale and licensing channels worldwide. The Company�� Retail/wholesale channel is engaged in the sale of luxury goods through Burberry mainline stores, concessions, outlets and digital commerce, as well as Burberry franchisees, prestige department stores globally and multi-brand specialty accounts. The Company�� retail channel includes approximately 206 mainline stores, 214 concessions within department stores, digital commerce and 49 outlets. The Company�� wholesale channel includes sales to department stores, multi-brand specialty accounts, Travel Retail and franchisees who operates approximately 65 Burberry stores. Advisors' Opinion:

• [By Jonathan Morgan]

  Burberry (BRBY) added 1.8 percent to 1,488 pence. Revenue climbed 17 percent to 1.03 billion pounds, while adjusted pretax profit for the six months ended Sept. 30 rose to 174 million pounds from 173 million pounds a year earlier, the London-based trenchcoat maker said in a statement.

• [By Alexis Xydias]

  Prudential Plc, Britain�� biggest insurer by market value, climbed 1.6 percent after saying nine-month sales rose 6 percent. Burberry (BRBY) Group Plc rose 0.6 percent after reporting first-half earnings.

5 Best Recreation Stocks To Invest In Right Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of recreational vehicle maker Thor Industries (NYSE: THO  ) popped 10% today after its quarterly results topped Wall Street expectations.

So what: The stock has rallied nicely over the past year on rebounding consumer spending, and today's third-quarter results -- profit increased 6% on a 13% jump in revenue -- suggest that things are only getting better. While markets remain competitive, Thor is entering the peak RV selling season, when demand improves and discounting slows, giving analysts plenty of optimism over its margin growth in 2013.

Now what: Don't expect the operating momentum to slow anytime soon. "Our results for the third quarter reflect the dealer optimism and improved retail consumer demand that has been building since the beginning of the year," said Chairman and CEO Peter Orthwein. "Based on the current positive momentum we see in our markets, we are confident in our ability to generate growth in sales and earnings for the remainder of the year." With the stock now up more than 70% from its 52-week lows and trading at a near-20 P/E, however, much of that growth might already be baked into the price.� �

Top 5 Biotech Companies To Watch In Right Now: Medina International Holdings Inc (MIHI)

Medina International Holdings, Inc. (Medina), incorporated on June 23, 1998, manufactures products and services to assist emergency and defense organizations and personnel. The Company, through its two wholly owned subsidiaries, Harbor Guard Boats, Inc. (HGB) and Medina Marine, Inc. manufactures and sells recreational and commercial boats. The products are manufactured by HGB, which designs, manufactures, and markets hand-laid fiberglass and aluminum commercial boats ranging from 15 feet to 37 feet, which are utilized by fire, search and rescue, emergency, patrol, military and defense organizations. It manufactures commercial and recreational watercrafts.

As of April 30, 2012, HGB had nine models of commercial and recreational watercrafts. The Company�� products consist of commercial boats and recreational boats. As of April 30, 2012, Medina had seven commercial watercraft models, ranging from 15 feet to 37 feet in length. Its other watercraft includes 15 feet interceptor, which is used for rescue and fiber glass; 20-feet interceptor, which is used for fire rescue, rescue and fiber glass; 21 feet firecat, which is used for fire rescue, rescue and fiber glass; 24 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 26 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 30 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass, and 37 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass. As of April 30, 2012, the Company had two recreational watercraft models. Its watercraft products are made out of fiberglass and aluminum materials.

Advisors' Opinion:

• [By Peter Graham]

  Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:

5 Best Recreation Stocks To Invest In Right Now: Vitamin Blue Inc (VTMB)

Vitamin Blue, Inc. (Vitamin Blue), incorporated on May 25, 1999, is engaged in designing, manufacturing and distributing surf wear board shorts, t-shirts and fleece jackets) and surfing accessories (surf boards bags, roof rack pad and surf backpacks). The Company focuses on four types of retail outlets: surfboard manufacturers, surf shops, specialty stores and department stores. Vitamin Blue distributes the majority of its products through surfboard manufacturers and surf shops. The primary focus of Vitamin Blue is surf wear and surfing accessories. The Company�� primary distribution focuses on retail outlets in North America (the United States, Canada and Mexico). Vitamin Blue manufactures most of its surfing accessories and all of its surfwear in-house.

Surfboard Manufacturers

The Company�� surfboard manufactures retail outlet generally consists of single shops, where surfboards are designed, manufactured and marketed. It is the source for surfing accessories. This distribution channel focuses on the core surf market. The Company has relationships with manufacturers, such as Hap Jacobs, Bing Surfboards, Bark Boards and Ron House Shapes, Dewey Weber, Stewart Surfboards. Vitamin Blue surfing accessories are sold through this channel.

Surf Shops

The Company�� surf shops are generally single to multiple shops located in or near beach cities, focused on the central surf market. It tends to be privately owned. Surf shops also focus on the core surf market and provide an authentic retail source for complete lines of surfwear and surfing accessory products. The Company has relationships with manufacturers, such as Freeline Design (Santa Cruz, California), The Frog House (Newport Beach, California), Infinity Surfboards (Dana Point, California), Legends Surf (Carlsbad, California), Hi-Tech Surf Sports (Maui, Hawaii), Second Wind Sail and Surf (Maui, Hawaii), Hawaiian Island Surf and Sport (Maui, Hawaii) Kennedy Surfboards (Woodland Hills, California),! Malibu Surf Shack, (Malibu, California), E.T. Surf (Hermosa Beach, California), Spyder (Hermosa Beach, California), Costa Azul (Laguna Beach, California), Icons of Surf (San Clemente, California), Encinitas Surfboards (Encinitas, California), Nor Easter Surf Shop (Scituate, Massachusetts), Air & Speed Surf Shop (Montauk, New York), Xtreme Surf & Sport (East Northport, New York) and Marsh�� Surf Shop (Atlantic Beach, North Carolina). The complete line of Vitamin Blue products (surfwear and surfing accessories) is distributed through this channel.

Specialty Stores

The Company�� specialty stores type of retail outlet generally consists of single, regional and nationwide stores, and tends to be located in or near beach or resort communities, shopping centers, and shopping malls. Specialty stores distributing surf products primarily include tourist/vacation shops, sporting good stores (including Sports Chalet, Inc. - SPCHB), and regional and national retail stores (including Pacific Sunwear of California-PSUN and Zumiez, Inc.-ZUMZ). Vitamin Blue intends to use this type of retail outlet to distribute its surfwear.

Department Stores

The Company�� department stores type of retail outlet generally has stores located nationwide. It is located in shopping malls, such as Bloomingdale��, Macy��, Saks Fifth Avenue and Nordstrom. Vitamin Blue intends to use this type of retail outlet to distribute its surfwear.

Vitamin Blue�� surfing accessories include surfboard travel bags, which offer surfboard protection and can be used daily or for long distance surf trips; surf gear travel bags, which are duffle bags used to carry surfing essentials on surf trips; surf backpacks, which are specially, designed wet bag backpacks for wetsuit storage, and roof-rack pads, which is used on existing car roof racks for surfboard protection and security on daily surf outings.

The Company competes with Quicksilver, Inc., Billabong Intl, Hurley and! Volcom I! nc.

Advisors' Opinion:

• [By Peter Graham]

  Small cap marijuana stocks Smart Ventures Inc (OTCMKTS: SMVR) and Vitamin Blue Inc (OTCMKTS: VTMB) jumped 40.28% and 38.6%, respectively, while hemp stock Astika Holdings Inc (OTCBB: ASKH) fell 13.75% on Friday. Moreover, only one of these small cap stocks seems to have been the subject of a few paid promotions or investor relations types of activities. So will all three of these marijuana or hemp stocks keep producing highs or lows for investors and traders alike? Here is a quick reality check:

• [By Peter Graham]

  Small cap stocks Green Endeavors Inc (OTCMKTS: GRNE), Global Links Corporation (OTCMKTS: GLCO) and Vitamin Blue Inc (OTCBB: VTMB) were all making noticeable moves at the end of last week. On Friday, Green Endeavors Inc rose 8.11% and Global Links Corporation rose 13.96% while Vitamin Blue Inc fell 10%. Of course, small cap OTC stocks making large single digit or double digit moves in either direction aren�� all that unusual. Moreover, all of these small caps have been the subject of paid promotions. With that in mind, here is a closer look at all three to help you decide on an investing or trading strategy:

5 Best Recreation Stocks To Invest In Right Now: IMAX Corp (IMAX)

IMAX Corporation, incorporated on January 1, 2002, together with its wholly owned subsidiaries, is an entertainment technology companies, specializing in motion picture technologies and presentations. The Company�� customers who purchase lease or otherwise acquire the IMAX theatre systems are theatre exhibitors, which operate commercial theatres, museums, science centers, and destination entertainment sites. IMAX theatre systems combine the Company�� digital re-mastering movie conversion technology (IMAX DMR), projectors with equipment and automated theatre control systems, sound system components, screens, theatre geometry, and theatre acoustics.

The Company�� principal business is the design, manufacture and delivery of theater systems (IMAX theater systems). The Company�� customers who purchase, lease or otherwise acquire the IMAX theater systems through joint revenue sharing arrangements are theater exhibitors that operate commercial theaters (particularly multiplexes), museums, science centers, or destination entertainment sites. The Company does not own IMAX theaters, but licenses the use of its trademarks along with the sale, lease or contribution of the IMAX theater system.

IMAX Systems, Theater System Maintenance and Joint Revenue Sharing Arrangements

The Company provides IMAX theater systems to customers on a sales or long-term lease basis with an initial 10-year term. These agreements consist of initial fees and ongoing fees (which can include a fixed minimum amount per annum and contingent fees in excess of the minimum payments) and maintenance and extended warranty fees. The initial fees vary depending on the system configuration and location of the theater and generally are paid to the Company in installments between the time of system signing and the time of system installation. Ongoing fees are paid over the term of the contract, commencing after the theater system has been installed and are generally equal to the greater of a fixed minimu! m amount per annum or a percentage of boxoffice receipts. The Company also provides IMAX theater systems to customers under joint revenue sharing arrangements, pursuant to which the Company provides the IMAX theater system in return for a portion of the customer�� IMAX box-office receipts, and in some cases concession revenues and/or a small upfront or initial payment. As at December 31, 2012, the Company had 316 theaters in operation under joint revenue sharing arrangements.

Production and Digital Re-Mastering (IMAX DMR)

The Company�� technology digitally re-masters Hollywood films into IMAX digital cinema package format or 15/70-format film. IMAX DMR digitally enhances the image resolution of motion picture films for projection on IMAX screens while maintaining or enhancing the visual clarity and sound quality to levels for which The IMAX Experience is known. This technology enabled the IMAX theater network to release Hollywood films simultaneously with domestic release. In a typical IMAX DMR film arrangement, the Company will receive a percentage of net box-office receipts of any commercial films released in the IMAX network, which is generally 10-15%, from a film studio for the conversion of the film to the IMAX DMR format and access to its distribution platform. During the year ended December 31, 2012, 35 films converted through the IMAX DMR process were released to theaters within the IMAX network. As of December 31, 2012, the Company released 23 IMAX DMR titles to theaters within the IMAX network. During 2012, five local language IMAX DMR films were released, including one French film, Houba! On the Trail of the Marsupilami: The IMAX Experience and four Chinese IMAX DMR titles: Tai Chi 0: An IMAX 3D Experience, Tai Chi Hero: An IMAX 3D Experience, Back to 1942: The IMAX Experience and CZ12: The IMAX Experience.

Film Distribution and Post-Production

The Company is also a distributor of large-format films, primarily catering to its institution! al theate! r partners. The Company generally distributes films, which it produces or for which it has acquired distribution rights from independent producers. The Company generally receives a percentage of the theater box-office receipts as a distribution fee. Films produced by the Company are typically financed through third parties, whereby the Company will generally receive a film production fee in exchange for producing the film and a distribution fee for distributing the film. The Company utilizes third-party funding for the majority of original films it produces and distributes. In 2012, the Company, along with Warner Bros. Pictures (WB) and MacGillivray Freeman Films (MFF) released an original title, To the Artic 3D: An IMAX 3D Experience.

The Company derives a small portion of its revenues from other sources. As of December 31, 2012, the Company had four owned and operated theaters. In addition, the Company has a commercial arrangement with one theater resulting in the sharing of profits and losses and provides management services to two theaters. The Company also rents its two dimensional (2D) and three dimensional (3D) large-format film and digital cameras to third party production companies. The Company maintains cameras and other film equipment and also offers production advice and technical assistance to both documentary and Hollywood filmmakers. Additionally, the Company generates revenues from the sale of after-market parts and 3D glasses. As of December 31, 2012, approximately 54.2% of IMAX systems in operation were located in the United States and Canada. As at December 31, 2012, approximately 45.8% of IMAX systems in operation were located within international markets (other than the United States and Canada).

Advisors' Opinion:

• [By Rich Smith]

  This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of upgrades for AT&T (NYSE: T  ) and IMAX (NYSE: IMAX  ) . But the news isn't all good, so before we get to those, let's find out first why...

• [By Jake L'Ecuyer]

  Imax (NYSE: IMAX) was down, falling 8.38 percent to $26.02 after Cormark Securities downgraded the stock from Market Perform to Reduce.

  Commodities

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, jumbo-movie-screen systems maker IMAX (NYSE: IMAX  ) has earned a respected four-star ranking.

5 Best Recreation Stocks To Invest In Right Now: Mountain China Resorts Holding Ltd (MCG)

Mountain China Resorts (Holding) Limited (MCR) is a Canada-based investment holding company. The Company is a Mountain resort developer in the People�� Republic of China. The Company�� subsidiaries engaged in the development and operation of mountain resorts and provision of hotel services in the People's Republic of China. The Company holds 100% interest in Mountain China Resorts Investment Limited, which in turn holds 100% interest in Mountain China Resorts Limited. The Company owns and operates the ski resort in the People�� Republic of China, Sun Mountain Yabuli Resort in Heilongjiang Province. The Sun Mountain Yabuli Resort also has two luxury five star hotels, restaurants, spa, retail, and conference facilities. It holds 140 million square meters of land for commercial development purpose around the Sun Mountain Yabuli Resort. As of December 31, 2011, the Company�� resort real estate development project was at the Sun Mountain Yabuli Resort. Advisors' Opinion:

• [By ICRAOnline]

  Apart from the Data Center Group, Intel expects the Axxia deal to boost the performance of the other two segments ��Internet of Things Group (IoTG) and Mobile and Communications Group (MCG).

Top 5 Heal Care Companies To Buy Right Now

Recent market uncertainty prompted by the continued Federal Reserve tapering discussion and the government shutdown in the U.S. has led to downwardly revised growth expectations as we head into next year. These expectations for renewed weakness in consumption and manufacturing present a clear negative for energy markets, as demand traditionally suffers in these types of slowing markets. But when we look at the broader trends in oil prices, it is clear that investors are reluctant to accept that these macroeconomic uncertainties will have a substantive effect on fourth-quarter market valuations. Even with the short-term declines we have seen in oil, correlated ETFs like the United States Oil Fund LP ETF (USO) are still showing strong gains on the year:

All of this creates strong underlying support for oil stocks going forward and actually suggests that the short-term declines seen since the summer months have created a buying opportunity rather than offering a reason to avoid the energy space based on what could be unnecessarily weak demand forecasts.

Best Railroad Stocks To Own Right Now: Associated Banc-Corp(ASBC)

Associated Banc-Corp, a bank holding company, offers various banking and financial services to individuals and businesses primarily in Wisconsin, Illinois, and Minnesota. Its Banking segment provides loans and deposit products to businesses, governments, and consumers. Its products and services include checking, savings, money market deposit, and IRA accounts, as well as certificates of deposit and safe deposit boxes; and home equity loans and lines of credit, residential mortgage loans and mortgage refinancing, education loans, and personal and installment loans. This segment?s products and services also include business checking accounts, business loans, real estate financing, construction loans, letters of credit, revolving credit arrangements, business credit cards, equipment and machinery leases, night depository, cash management, international banking, check clearing, safekeeping, and other banking-based services. The company?s Wealth Management segment provides va rious fiduciary, investment management, advisory, and corporate agency services for individuals, corporations, small businesses, charitable trusts, endowments, foundations, and institutional investors. This segment also offers life, property, casualty, and credit and mortgage insurance, as well as fixed annuities and employee group benefits consulting and administration services; investment brokerage, variable annuities, and discount and online brokerage services; and trust/asset/investment management, administration of pension, profit-sharing and other employee benefit plans, personal trusts, and estate planning services. The company offers its products through branch facilities, loan production offices, supermarket branches, a customer service call center, an interstate automated teller machine network, and Internet banking services. As of December 31, 2010, its banking subsidiary had 280 offices in approximately 150 communities. The company was founded in 1964 and is base d in Green Bay, Wisconsin.

Advisors' Opinion:

• [By Marc Bastow]

  Green Bay-based bank holding company Associated Banc Corp (ASBC) raised its quarterly dividend 12.5% to 9 cents per share, payable on Dec. 16 to shareholders of record as of Dec. 2.
  ASBC Dividend Yield:�2.19%

• [By John Maxfield]

  Given that you clicked on this article, it seems safe to assume you either own stock in Associated Banc-Corp. (NASDAQ: ASBC  ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about Associated Banc-Corp stock before deciding whether to buy, sell, or hold it.

• [By The Part-time Investor]

  The following stocks met the criteria in January of 2008 and were put into the initial portfolio:

  Abbot Labs (ABT)Advanced data processing (ADP)Associated Banc-Corp (ASBC)Bank of America (BAC)BB&T Corp. (BBT)Bemis Company (BMS)Anheuser Busch (BUD)The Chubb Corporation (CB)Clorox (CLX)Comerica Inc. (CMA)Diebold Inc. (DBD)Emerson Electronics (EMR)First Dollar Corp. (FDO)First Third BanCorp. (FITB)Gannett Co, Inc. (GCI)General Electric (GE)Hershey (HSY)Illinois Tools Works (ITW)Johnson and Johnson (JNJ)Leggett and Platt (LEG)Eli Lilly (LLY)La-Z-Boy (LZB)McDonald's (MCD)Marsh and Ilsley (MI)M&T Bancorp (MTB)PepsiCo (PEP)Pfizer (PFE)Procter & Gamble (PG)Pentair Ltd. (PNR)Regions Financial Corp. (RF)Rohm and Haas (ROH)RPM International (RPM)Sherwin Williams (SHW)Sysco Corp. (SYY)UDR Inc. (UDR)

  Historical quotes were taken from Yahoo Finance. $10,000 was put into each position, to the nearest whole share, so a total of $349,262.89 was invested. From 1/15/08 through 5/16/13 all dividends were reinvested back into the stock that paid them. If a dividend cut was announced, that stock was sold on the ex-div date of the new, lower dividend.

Top 5 Heal Care Companies To Buy Right Now: Tile Shop Holdings Inc (TTS)

Tile Shop Holdings, Inc., incorporated on June 21, 2012, is a specialty retailer of manufactured and natural stone tiles, setting and maintenance materials, and related accessories in the United States. The Company sells over 4,500 products from around the world, including ceramic, porcelain, glass, and stainless steel manufactured tiles and, marble, granite, quartz, sandstone, travertine, slate, and onyx natural tiles. It purchases its tile products and accessories directly from producers. The Company manufactures its own setting and maintenance materials, such as thinset, grout, and sealers under its brand name. The Company operates 70 stores in 22 states, with an average size of 23,000 square feet. It also sells its products on its Website. In January 2014 Tile Shop Holdings Inc launched its first retail store in Oklahoma City.

The Company offers a complete assortment of tile products, generally sourced directly from producers, including ceramic, porcelain, glass, and stainless steel manufactured tiles, and marble, granite, quartz, sandstone, travertine, slate, and onyx natural tiles. The Company also offers a range of setting and maintenance materials, such as thinset, grout and sealers, and accessories, including installation tools, shower and bath caddies, drains, and similar products.

The Company competes with Home Depot, Tile America, World of Tile, Century Tile, and Floor and Decor, Dal-Tile and Florida Tile.

Advisors' Opinion:

• [By John Udovich]

  The shorts appear to be trying to crack small cap Tile Shop Holdings, Inc (NASDAQ: TTS)���meaning it might be worth taking a realistic look at the stock and any potential problems surrounding it plus the performance of other home improvement retailers or peers like Lumber Liquidators Holdings Inc (NYSE: LL), which is not into tiles, and The Home Depot, Inc (NYSE: HD) and Lowe's Companies, Inc (NYSE: LOW) which would be into tiles.

• [By Steve Symington]

  Almost two months ago, I singled out�Tile Shop Holdings� (NASDAQ: TTS  ) as one of�three great small-cap stocks�with which many investors might not be familiar. After all, the high-end stone and tile specialist still had a market capitalization under $800 million at the time, and only just went public late last year.

• [By Dan Caplinger]

  Stock market investors were generally pleased with the congressional testimony that Fed chair nominee Janet Yellen gave today, with new expectations that accommodative monetary policy will continue as long as any hint of economic weakness persists. The Dow and S&P 500 reached new record highs yet again, with Dow 16,000 and S&P 1,800 now within a single percentage point. But Cisco Systems (NASDAQ: CSCO  ) , Tile Shop Holdings (NASDAQ: TTS  ) , and Millennial Media (NYSE: MM  ) all missed the record run, falling by more than 10% each.

• [By Paul Ausick]

  Stocks on the Move: Houghton Mifflin Harcourt Co. (NASDAQ: HMHC) is up 32.2% at $15.86 after its IPO today. Tile Shop Holdings Inc. (NASDAQ: TTS) is down 39% at $12.95 following a short seller�� claim that profits were overstated. Hewlett-Packard Co. (NYSE: HPQ) is down 5.4% at $25.07 after halting sales of its Chromebook laptop due to an overheating charger problem.

Top 5 Heal Care Companies To Buy Right Now: Global Digital Creations Holdings Ltd (GDC)

Global Digital Creations Holdings Limited is an investment holding company. Through its subsidiaries, the Company operates in three segments: computer graphics (CG) and production segment, which includes CG creation, production and exhibition of motion pictures and production of television series and movies, as well as property rental income; CG training courses segment, engaged in the provision of CG and animation training, and cultural park segment, engaged in the media entertainment and related commercial property development. The Company�� subsidiaries include GDC Holdings Limited, GDC Asset Management Limited, GDC China Limited, GDC Digital Cinema Network Limited, GDC Digital Cinema Network Limited, GDC International Limited and GDC Management Services Limited, among others. On September 6, 2011, it completed the disposal of interests in GDC Technology Limited and GDC Digital Cinema Network Limited. Advisors' Opinion:

• [By Barel Karsan]

  If you follow Genesis Land (GDC), your head may be spinning by now. It's almost every day now that the current board and the activists trying to take it over are claiming some sort of injustice permeated by the other side. (To watch this battle in real-time, sign up for filing notifications for GDC here.) But surely, behind all the "Our directors are superior to yours" puffery, there are some differences in how each group would run the company differently.

Top 5 Heal Care Companies To Buy Right Now: Coinstar Inc.(CSTR)

Coinstar, Inc., through its subsidiaries, provides automated retail solutions primarily in the United States, Canada, Puerto Rico, Ireland, and the United Kingdom. The company owns and operates self-service Redbox kiosks that enable consumers to rent or purchase movies and video games; and self-service coin-counting kiosks where consumers can convert their coin to cash, a gift card, or an E-certificate. It also engages in identifying, evaluating, building, and developing new self-service concepts in the automated retail space, which includes coffee, refurbished electronics, and photo self-service concepts. As of December 31, 2011, the company had 35,400 Redbox kiosks in 29,300 locations and 20,200 coin-counting kiosks in 19,900 locations primarily in supermarkets, drug stores, mass merchants, financial institutions, convenience stores, and restaurants. Coinstar, Inc. was founded in 1991 and is headquartered in Bellevue, Washington.

Advisors' Opinion:

• [By Canadian Value]

  Position % of Fund Assets 1) First American Financial Corp. (FAF) 7.0% 2) Apple, Inc. (AAPL) 6.5% 3) Coinstar, Inc. (CSTR) 4.8% 4) EMC Corp. (EMC) 4.4% 5) Coach, Inc. (COH) 4.4% 6) Kohl's Corp. (KSS) 4.1% 7) Blucora, Inc. (BCOR) 4.0% 8) Tetra Tech, Inc. (TTEK) 3.1% 9) OM Group, Inc. (OMG) 3.0% 10) American International Group, Inc. (AIG) 2.8% TOTAL 44.1% One area that we believe still offers some value in the market is in high quality, large��ap technology stocks that may be momentarily out��f��avor as they transition from rapid growth to slower growth. In particular, we become interested when that transition is also accompanied by a change in capital allocation policies designed to return more cash to shareholders in the form of dividends and share repurchases. We believe that Apple and EMC are two of the absolute highest quality technology businesses in the world and both have recently announced very material, shareholder��friendly changes to how they will allocate capital.

Best Biotech Companies To Watch In Right Now

Popular Posts: Hottest Energy Stocks Now – HK QEP CLMT SDRL13 “Triple A” Stocks to Buy7 Biotechnology Stocks to Buy Now Recent Posts: Hottest Financial Stocks Now – ASPS MBI SF LPLA Biggest Movers in Healthcare Stocks Now – ALXN PODD ISIS REGN Hottest Technology Stocks Now – SATS WDAY P CGNX View All Posts

The grades of four aerospace and defense stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

10 Best Managed Healthcare Stocks For 2015: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Dendreon (NASDAQ: DNDN) was down as well, falling 7.25 percent to $3.07 as traders looked to take profits from Monday's rally.

  Commodities
  In commodity news, oil traded down 1.65 percent to $103.19, while gold traded down 1.02 percent to $1,336.80. Silver traded down 1.03 percent Tuesday to $21.20, while copper rose 0.78 percent to $3.21.

Best Biotech Companies To Watch In Right Now: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By MONEYMORNING]

  Cell Therapeutics Inc. (Nasdaq: CTIC), based in Seattle, Wash., acquires, develops, and commercializes treatments for cancers, including non-Hodgkin's leukemia and ovarian, neck, and brain cancers. The company just announced it has completed patient enrollment in clinical trials for an investigational agent to be used as a maintenance therapy in ovarian cancer patients. The trial is being conducted by the Gynecologic Oncology Group, one of the National Cancer Institute's funded research groups. Roth Capital recently reiterated a "Buy" rating on the stock and raised its price target from $6 to $7. Roth believes the company's treatment for leukemia, Pacritinib, is effectively evolving. Additionally, the investment firm sees potential in CTIC's Tosedostat, which deprives tumor cells of the amino acid building blocks needed to make proteins necessary for tumor cell survival. Shares rose 2% Tuesday to $3.52 on volume of 6 million shares.

• [By Sean Williams]

  Cell Therapeutics (NASDAQ: CTIC  )
  Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�

Best Biotech Companies To Watch In Right Now: Neurocrine Biosciences Inc.(NBIX)

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Lisa Levin]

  Neurocrine Biosciences (NASDAQ: NBIX) shares moved up 76.95% to $17.27. The volume of Neurocrine Biosciences shares traded was 4406% higher than normal. Neurocrine Biosciences reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Shares of Neurocrine Biosciences (NASDAQ: NBIX) got a boost, shooting up 57.43 percent to $15.37 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

• [By Ben Levisohn]

  Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.

• [By Ben Levisohn]

  Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
  (RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:

Best Biotech Companies To Watch In Right Now: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors' Opinion:

• [By Keith Speights]

  Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."

• [By Maxx Chatsko]

  Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.

Best Biotech Companies To Watch In Right Now: Vertex Pharmaceuticals Incorporated(VRTX)

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Ben Levisohn]

  After big rallies by biotech stocks, the folks at Weeden wondered if the rally getting overdone.�UBS analyst Matthew Roden and team think biotech stocks like Gilead Sciences�(GILD), Celgene�(CELG),�Vertex Pharmaceuticals (VRTX),�Puma Biotechnology (PBYI) and Achillion Pharmaceuticals (ACHN) can keep running. They explain why:

• [By Sean Williams]

  Then along came Vertex Pharmaceuticals (NASDAQ: VRTX  ) with its oral medication, Incivek, which drastically changed the treatment landscape. Although still given in combination with interferon and a ribavirin, Incivek greatly improved patients' sustained virologic response (the level at which no detectable levels of the HCV virus can be found) after 24 weeks by 20% to 45% over the previous standard of treatment depending on the trial. Not surprisingly, Incivek became the quickest drug to ever reach $1 billion in sales (less than eight months), but also lost the majority of its revenue nearly as fast as it ceded ground to up-and-coming treatments.�

• [By Investing Insight]

  Innovation is the critical success factor for the biotechnology industry. As long as the companies in this industry are able to get new drugs approved by the U.S. Food and Drug Administration (FDA) before their earlier patents expire, all is good to go. Vertex Pharmaceuticals (VRTX) is an active player in this industry. Let's take a look at how this company has been tackling the challenging economic conditions in the US and what the future holds for its shareholders.

• [By Alex Dumortier, CFA]

  The 60% return that Vertex Pharmaceuticals (NASDAQ: VRTX  ) achieved in a single day last month on the test results of a cystic-fibrosis drug is the sort of thing that gets investors' salivary glands flowing. (This is not an illiquid micro-cap stock, by the way; with a market capitalization that exceeds $17 billion, Vertex is a large-cap issue.)